Zhi-Ming Li (Zhiming Li)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 41

Top Topics

Epstein Barr Virus

Hodgkin Lymphoma

Histone Deacetylase

Top Venues

Signal transduction and targeted therapy

Cancer medicine

Biomarkers in medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Zhi-Ming Li, Xiang Li, Su Li, Rong Tao, Xin Tian, Fan Feng, Wenqi Jiang, Huaqing Wang
Preclinical evaluation and phase 1 study of the PI3Kα/δ inhibitor TQ-B3525 in Chinese patients with advanced cancers. Cancer (2024)
Huaqing Wang, Jifeng Feng, Yanyan Liu, Zhengzi Qian, Da Gao, Xuehong Ran, Hui Zhou, Lihong Liu, Binghua Wang, Meiyun Fang, Hebing Zhou, Zhenqian Huang, Shi Tao, Zhuowen Chen, Liping Su, Hang Su, Yu Yang, Xiaobao Xie, Huijing Wu, Ping Sun, Guoyu Hu, Ai-Bin Liang, Zhi-Ming Li
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma. Signal transduction and targeted therapy 9 (1) (2024)
Zegeng Chen, He Huang, Huageng Huang, Le Yu, Huawei Weng, Jian Xiao, Liqun Zou, Huilai Zhang, Chaoyong Liang, Hui Zhou, Hongqiang Guo, Zhao Wang, Zhi-Ming Li, Tao Wu, Hongyu Zhang, Huijing Wu, Zhigang Peng, Linzhu Zhai, Xinggui Chen, Zhi-Wei Liang, Huangming Hong, Tongyu Lin
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma. Leukemia 38 (4) (2024)
Di Wu, Yong Li, Pengfei Xu, Qi Fang, Fei Cao, Hongsheng Lin, Yin Li, Yong Su, Lixia Lu, Lei Chen, Yizhuo Li, Zheng Zhao, Xiaoyu Hong, Guohong Li, Yaru Tian, Jinyun Sun, Honghong Yan, Yunyun Fan, Xinrui Zhang, Zhi-Ming Li, Xue-Kui Liu
Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. Nature communications 15 (1) (2024)
Jie Jin, Hong Cen, Ke-Shu Zhou, Xiaohong Xu, Fei Li, Tao Wu, Haiyan Yang, Zhen Wang, Zhi-Ming Li, Wenyang Huang, Hanying Bao, Zusheng Xu, Lugui Qiu
A Phase Ib Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Zegeng Chen, He Huang, Huageng Huang, Le Yu, Huawei Weng, Jian Xiao, Liqun Zou, Huilai Zhang, Chaoyong Liang, Hui Zhou, Hongqiang Guo, Zhao Wang, Zhi-Ming Li, Tao Wu, Hongyu Zhang, Huijing Wu, Zhigang Peng, Linzhu Zhai, Xinggui Chen, Zhi-Wei Liang, Huangming Hong, Tongyu Lin
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma. Leukemia (2024)
Huaqing Wang, Jifeng Feng, Yanyan Liu, Zhengzi Qian, Da Gao, Xuehong Ran, Hui Zhou, Lihong Liu, Binghua Wang, Meiyun Fang, Hebing Zhou, Zhenqian Huang, Shi Tao, Zhuowen Chen, Liping Su, Hang Su, Yu Yang, Xiaobao Xie, Huijing Wu, Ping Sun, Guoyu Hu, Ai-Bin Liang, Zhi-Ming Li
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma. Signal transduction and targeted therapy 9 (1) (2024)
Di Wu, Yong Li, Pengfei Xu, Qi Fang, Fei Cao, Hongsheng Lin, Yin Li, Yong Su, Lixia Lu, Lei Chen, Yizhuo Li, Zheng Zhao, Xiaoyu Hong, Guohong Li, Yaru Tian, Jinyun Sun, Honghong Yan, Yunyun Fan, Xinrui Zhang, Zhi-Ming Li, Xue-Kui Liu
Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. Nature communications 15 (1) (2024)
Huaqing Wang, Jifeng Feng, Yanyan Liu, Zhengzi Qian, Da Gao, Xuehong Ran, Hui Zhou, Lihong Liu, Binghua Wang, Meiyun Fang, Hebing Zhou, Zhenqian Huang, Shi Tao, Zhuowen Chen, Liping Su, Hang Su, Yu Yang, Xiaobao Xie, Huijing Wu, Ping Sun, Guoyu Hu, Ai-Bin Liang, Zhi-Ming Li
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma. Signal transduction and targeted therapy 9 (1) (2024)
Yuqin Song, Zhengming Jin, Zhi-Ming Li, Yan-Yan Liu, Lanfang Li, Chuan He, Hang Su, Hui Zhou, Kunyan Li, Siguo Hao, Xuelan Zuo, Jianyuan Wu, Xiaojian Zhu, Meng Wu, Xiuhua Sun, Junyuan Qi, Zhen Cai, Zhenjiang Li, Yijing Li, Yanhua Huang, Jie Shen, Zhenyu Xiao, Jun Zhu
Enhancer of zeste homolog 2 inhibitor SHR2554 in relapsed or refractory peripheral T-cell lymphoma: data from the first-in-human phase 1 study. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Yan Gao, Haixia He, Xueping Li, Liling Zhang, Wei Xu, Ru Feng, Wenyu Li, Yin Xiao, Xinxiu Liu, Yu Chen, Xiaoxiao Wang, Bing Bai, Huijing Wu, Qing-Qing Cai, Zhi-Ming Li, Weiwei Xiao, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jiaying Mao, Xiujin Chen, Baitian Zhao, Huiqiang Huang
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study. Signal transduction and targeted therapy 9 (1) (2024)
Zegeng Chen, He Huang, Huageng Huang, Le Yu, Huawei Weng, Jian Xiao, Liqun Zou, Huilai Zhang, Chaoyong Liang, Hui Zhou, Hongqiang Guo, Zhao Wang, Zhi-Ming Li, Tao Wu, Hongyu Zhang, Huijing Wu, Zhigang Peng, Linzhu Zhai, Xinggui Chen, Zhi-Wei Liang, Huangming Hong, Tongyu Lin
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma. Leukemia 38 (4) (2024)
Zegeng Chen, He Huang, Huageng Huang, Le Yu, Huawei Weng, Jian Xiao, Liqun Zou, Huilai Zhang, Chaoyong Liang, Hui Zhou, Hongqiang Guo, Zhao Wang, Zhi-Ming Li, Tao Wu, Hongyu Zhang, Huijing Wu, Zhigang Peng, Linzhu Zhai, Xinggui Chen, Zhi-Wei Liang, Huangming Hong, Tongyu Lin
Genomic features reveal potential benefit of adding anti-PD-1 immunotherapy to treat non-upper aerodigestive tract natural killer/T-cell lymphoma. Leukemia 38 (4) (2024)
Yuqin Song, Zhengming Jin, Zhi-Ming Li, Yan-Yan Liu, Lanfang Li, Chuan He, Hang Su, Hui Zhou, Kunyan Li, Siguo Hao, Xuelan Zuo, Jianyuan Wu, Xiaojian Zhu, Meng Wu, Xiuhua Sun, Junyuan Qi, Zhen Cai, Zhenjiang Li, Yijing Li, Yanhua Huang, Jie Shen, Zhenyu Xiao, Jun Zhu
Enhancer of Zeste Homolog 2 Inhibitor SHR2554 in Relapsed or Refractory Peripheral T-cell Lymphoma: Data from the First-in-Human Phase I Study. Clinical cancer research : an official journal of the American Association for Cancer Research 30 (7) (2024)
Di Wu, Yong Li, Pengfei Xu, Qi Fang, Fei Cao, Hongsheng Lin, Yin Li, Yong Su, Lixia Lu, Lei Chen, Yizhuo Li, Zheng Zhao, Xiaoyu Hong, Guohong Li, Yaru Tian, Jinyun Sun, Honghong Yan, Yunyun Fan, Xinrui Zhang, Zhi-Ming Li, Xue-Kui Liu
Neoadjuvant chemo-immunotherapy with camrelizumab plus nab-paclitaxel and cisplatin in resectable locally advanced squamous cell carcinoma of the head and neck: a pilot phase II trial. Nature communications 15 (1) (2024)
Yan Gao, Haixia He, Xueping Li, Liling Zhang, Wei Xu, Ru Feng, Wenyu Li, Yin Xiao, Xinxiu Liu, Yu Chen, Xiaoxiao Wang, Bing Bai, Huijing Wu, Qing-Qing Cai, Zhi-Ming Li, Weiwei Xiao, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jiaying Mao, Xiujin Chen, Baitian Zhao, Huiqiang Huang
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study. Signal transduction and targeted therapy 9 (1) (2024)
Yan Gao, Haixia He, Xueping Li, Liling Zhang, Wei Xu, Ru Feng, Wenyu Li, Yin Xiao, Xinxiu Liu, Yu Chen, Xiaoxiao Wang, Bing Bai, Huijing Wu, Qing-Qing Cai, Zhi-Ming Li, Weiwei Xiao, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jiaying Mao, Xiujin Chen, Baitian Zhao, Huiqiang Huang
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study. Signal transduction and targeted therapy 9 (1) (2024)
Yan Gao, Haixia He, Xueping Li, Liling Zhang, Wei Xu, Ru Feng, Wenyu Li, Yin Xiao, Xinxiu Liu, Yu Chen, Xiaoxiao Wang, Bing Bai, Huijing Wu, Qing-Qing Cai, Zhi-Ming Li, Weiwei Xiao, Suxia Lin, Yanxia He, Liqin Ping, Cheng Huang, Jiaying Mao, Xiujin Chen, Baitian Zhao, Huiqiang Huang
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study. Signal transduction and targeted therapy 9 (1) (2024)
Huaqing Wang, Jifeng Feng, Yanyan Liu, Zhengzi Qian, Da Gao, Xuehong Ran, Hui Zhou, Lihong Liu, Binghua Wang, Meiyun Fang, Hebing Zhou, Zhenqian Huang, Shi Tao, Zhuowen Chen, Liping Su, Hang Su, Yu Yang, Xiaobao Xie, Huijing Wu, Ping Sun, Guoyu Hu, Ai-Bin Liang, Zhi-Ming Li
Phase II study of novel orally PI3Kα/δ inhibitor TQ-B3525 in relapsed and/or refractory follicular lymphoma. Signal transduction and targeted therapy 9 (1) (2024)
Xiaoqing Sun, Jianghua Cao, Peng Sun, Hang Yang, Huan Li, Wenjuan Ma, Xianqiu Wu, Xiaohua He, Jing Li, Zhi-Ming Li, Jiajia Huang
Pretreatment soluble Siglec-5 protein predicts early progression and R-CHOP efficacy in diffuse large B-cell lymphoma. Biomarkers in medicine 17 (3) (2023)
Tianxiao Gao, Jieye Huang, Haofan Yin, Jiajia Huang, Jinye Xie, Ti Zhou, Wei Fan, Xia Yang, Guoquan Gao, Zhi-Ming Li
Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase. Cell death & disease 14 (5) (2023)
Tianxiao Gao, Jieye Huang, Haofan Yin, Jiajia Huang, Jinye Xie, Ti Zhou, Wei Fan, Xia Yang, Guoquan Gao, Zhi-Ming Li
Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase. Cell death & disease 14 (5) (2023)
Zhiming Li, Hang Yang, Baitian Zhao, Yu Wang, Man Nie, Kangming Huang, Zhi-Ming Li
Outcomes of COVID-19 in patients with lymphomas participating in registered clinical trials: A real-world study from China in the Omicron outbreak era. Cancer medicine (2023)
Xiaoqing Sun, Jianghua Cao, Peng Sun, Hang Yang, Huan Li, Wenjuan Ma, Xianqiu Wu, Xiaohua He, Jing Li, Zhi-Ming Li, Jiajia Huang
Pretreatment soluble Siglec-5 protein predicts early progression and R-CHOP efficacy in diffuse large B-cell lymphoma. Biomarkers in medicine 17 (3) (2023)
Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhi-Ming Li, Yuqin Song, Li Zhang, Xiaojian Zhu, Huijing Wu, Wei Zhang, Junmin Li, Ke-Shu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zhenjiang Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
The oral PI3Kδ inhibitor linperlisib for the treatment of relapsed and/or refractory follicular lymphoma: A phase 2, single-arm, open-label clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Xiaoqing Sun, Jianghua Cao, Peng Sun, Hang Yang, Huan Li, Wenjuan Ma, Xianqiu Wu, Xiaohua He, Jing Li, Zhi-Ming Li, Jiajia Huang
Pretreatment soluble Siglec-5 protein predicts early progression and R-CHOP efficacy in diffuse large B-cell lymphoma. Biomarkers in medicine 17 (3) (2023)
Tianxiao Gao, Jieye Huang, Haofan Yin, Jiajia Huang, Jinye Xie, Ti Zhou, Wei Fan, Xia Yang, Guoquan Gao, Zhi-Ming Li
Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase. Cell death & disease 14 (5) (2023)
Xiaoqing Sun, Jianghua Cao, Peng Sun, Hang Yang, Huan Li, Wenjuan Ma, Xianqiu Wu, Xiaohua He, Jing Li, Zhi-Ming Li, Jiajia Huang
Pretreatment soluble Siglec-5 protein predicts early progression and R-CHOP efficacy in diffuse large B-cell lymphoma. Biomarkers in medicine 17 (3) (2023)
Lijuan Deng, Zhi-Ming Li, Huilai Zhang, Haiwen Huang, Jian-da Hu, Lihong Liu, Ting Liu, Jie Jin, Zunmin Zhu, Wenyu Li, Zhenqian Huang, Wenrong Huang, Ke-Shu Zhou, Haiyan Yang, Mingzhi Zhang, Kaiyang Ding, Hui Zhou, Han Yan, Yuerong Shuang, Junning Cao, Sujun Gao, Dengju Li, Zimin Sun, Qingyuan Zhang, Shuhua Yi, Chun-Yan Ji, Liansheng Zhang, Cheng Hou, Yue Du, Weige Wang, Renbin Zhao, Yuqin Song, Jun Zhu
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study. American journal of hematology (2023)
Zhiming Li, Yajun Li, Cong Li, Kexing Ren, Yu Wang, Hang Yang, Wenqi Jiang, Liqun Zou, Haiyan Yang, Hui Zhou, Zhi-Ming Li
A Phase II Study of Sintilimab, Anlotinib, and Pegaspargase Sandwiched with Radiotherapy as First-line Therapy in Patients with Newly Diagnosed, Stage I-II Extranodal Natural-killer/T-cell Lymphoma. American journal of hematology (2023)
Tianxiao Gao, Jieye Huang, Haofan Yin, Jiajia Huang, Jinye Xie, Ti Zhou, Wei Fan, Xia Yang, Guoquan Gao, Zhi-Ming Li
Inhibition of extranodal NK/T-cell lymphoma by Chiauranib through an AIF-dependent pathway and its synergy with L-asparaginase. Cell death & disease 14 (5) (2023)
Xiaoqing Sun, Jianghua Cao, Peng Sun, Hang Yang, Huan Li, Wenjuan Ma, Xianqiu Wu, Xiaohua He, Jing Li, Zhi-Ming Li, Jiajia Huang
Pretreatment soluble Siglec-5 protein predicts early progression and R-CHOP efficacy in diffuse large B-cell lymphoma. Biomarkers in medicine (2023)
Yuchen Zhang, Pan-Pan Liu, Jun Cai, Hongmei Jing, Liqun Zou, Huiqiang Huang, Yuanbin Wu, Wenyu Li, Liye Zhong, Xueli Jin, Xu Ye, Ru Feng, Huilai Zhang, Liling Zhang, Lie Lin, Xiuhua Sun, Yuyang Tian, Zhongjun Xia, Zhi-Ming Li, He Huang, Yi Xia, Qing-Qing Cai
Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study. Cancer medicine 11 (22) (2022)
Chong Wei, Wei Li, Liping Qin, Shan Liu, Chang Xue, Kexing Ren, Zirong Zhang, Caili Liu, Fang Bao, Huilai Zhang, Hui Zhou, Zhi-Ming Li, Huijing Wu, Liqun Zou, Lihong Liu, Hongmei Jing, Wei Zhang
Clinicopathologic characteristics, outcomes, and prognostic factors of angioimmunoblastic T-cell lymphoma in China. Cancer medicine (2022)
Xiaohua He, Yinglu Xiao, Shan Liu, Ruyan Deng, Zhi-Ming Li, Xianying Zhu
Predicting the Immune Microenvironment and Prognosis with a NETosis-Related lncRNA Signature in Head and Neck Squamous Cell Carcinoma. BioMed research international 2022 (2022)
Hai-Xia He, Yan Gao, Bing Bai, Xiao-Xiao Wang, Weiwei Xiao, Cheng Huang, Jia-Ying Mao, Li-Qin Ping, Qi-Xiang Rong, Yan-Xia He, He Huang, Qing-Qing Cai, Zhi-Ming Li, Wen-Qi Jiang, Hui-Qiang Huang
The beneficial effect of Escalated-R-CHOP-21 for the treatment of diffuse large B-cell lymphoma in elderly male patients: A propensity-matched cohort study. Cancer medicine 10 (21) (2021)
Xiaoqing Sun, Caiqin Wang, Cui Chen, Jiajia Huang, Xianqiu Wu, Yu Wang, Xiaohua He, Jianghua Cao, Wenqi Jiang, Peng Sun, Zhi-Ming Li
Combined tumor-associated macrophages biomarker predicting extremely poor outcome of patients with primary central nervous system lymphoma. Hematological oncology 39 (5) (2021)
Caiqin Wang, Yu Wang, Jianghua Cao, Xiaoqing Sun, Xiaohua He, Peng Sun, Tianxiao Gao, Jiajia Huang, Zhi-Ming Li
Elevated expression of HMGB1 is prognostic of poor survival in patients with relapsed/refractory T/NK-CL. Annals of hematology 100 (9) (2021)
Pei-Dong Chi, Yi-Jun Liu, Yu-Hua Huang, Ming-Jie Mao, Yu Wang, Zhi-Ming Li, Jian Li
Rinsing sampling of core needle biopsy for flow cytometric analysis: A favorable method for lymphoma diagnosis. Cancer medicine 9 (24) (2020)
Ke Wu, Xiao-Qing Sun, Cai-Qin Wang, Tian-Xiao Gao, Peng Sun, Yu Wang, Wen-Qi Jiang, Zhi-Ming Li, Jia-Jia Huang
Metronomic combination chemotherapy using everolimus and etoposide for the treatment of non-Hodgkin lymphoma. Cancer medicine 8 (10) (2019)
Pan-Pan Liu, Yi Xia, Xi-Wen Bi, Yu Wang, Peng Sun, Hang Yang, Zhi-Ming Li, Wen-Qi Jiang
Trends in Survival of Patients with Primary Gastric Diffuse Large B-Cell Lymphoma: An Analysis of 7051 Cases in the SEER Database. Disease markers 2018 (2018)